Mymd Pharmaceuticals (QCLS) Stock Price, News & Analysis

Company Overview

MyMD Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for immune-mediated diseases, inflammation and age-related conditions. The company has historically pursued treatments designed to regulate the immune system and address biological processes associated with chronic disease and aging.

MyMD’s principal investigational product has been MYMD-1, an orally administered small-molecule therapy intended to modulate immune and inflammatory responses. The company has also explored cannabidiol-based and other therapeutic approaches for potential applications in autoimmune disease, inflammation and related conditions. These products remain investigational and are subject to clinical and regulatory development.

MyMD Pharmaceuticals has been headquartered in the United States and has focused primarily on research and development rather than commercialized products. Publicly available information identifies the company’s historical Nasdaq ticker as MYMD; the symbol QCLS may not correspond to MyMD Pharmaceuticals. Because of this ticker discrepancy and limited current information, readers should verify the company’s present corporate status, leadership and listing details through its latest regulatory filings.

Key Stats

• Today's Range: $0.52 to $0.56
• 50-Day Range: $0.44 to $2.95
• 52-Week Range: $0.42 to $8.17
• Volume: 156,575 shs
• Average Volume: 2.12 million shs
• Market Capitalization: $4.42 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Mymd Pharmaceuticals Stock Analysis - MarketRank™

Mymd Pharmaceuticals scored higher than 21% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Mymd Pharmaceuticals has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Mymd Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Mymd Pharmaceuticals is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Mymd Pharmaceuticals is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Mymd Pharmaceuticals has a P/B Ratio of 0.10. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

11.67% of the float of Mymd Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Mymd Pharmaceuticals has a short interest ratio ("days to cover") of 0.04, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Mymd Pharmaceuticals has recently decreased by 50.24%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Mymd Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Mymd Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 4.3 / 5
• News Sentiment: 0.93

News Sentiment

Mymd Pharmaceuticals has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Technology companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Mymd Pharmaceuticals this week, compared to 0 articles on an average week.

Search Interest

3 people have searched for QCLS on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

MarketBeat Follows

2 people have added Mymd Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Mymd Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.86% of the stock of Mymd Pharmaceuticals is held by insiders.

Percentage Held by Institutions

9.64% of the stock of Mymd Pharmaceuticals is held by institutions.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 10/14/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Technology
• Industry: Technology Hardware, Storage & Peripherals
• Sub-Industry: Technology Hardware, Storage & Peripherals
• Current Symbol: NASDAQ:QCLS
• CIK: 1321834
• Web: www.qctechnologies.com
• Phone: (856) 848-8698
• Fax: 856-848-0269
• Employees: 2
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($3.48)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$11.63 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -91.64%
• Return on Assets: -47.48%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.29
• Quick Ratio: 3.29

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.19 per share
• Price / Book: 0.10

Miscellaneous

• Outstanding Shares: 8,190,000
• Free Float: 8,120,000
• Market Cap: $4.42 million
• Optionable: N/A
• Beta: 2.32